Elixiron Immunotherapeutics

Public

Elixiron Immunotherapeutics is now publicly traded

The data on this page reflects Elixiron Immunotherapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series B

Jun 12, 2025

Total Funding Raised

$70M

Company Overview

Elixiron Immunotherapeutics is a clinical-stage biotechnology company that develops precision immunotherapies for neuroinflammatory diseases, autoimmune diseases, and cancer.

AI Layer

Application

Keywords

immunotherapydrug discoverytherapeutic vaccinemonoclonal antibodybiotechoncologyinflammatory diseaseai drug discoveryclinical-stage biotechbiopharmaprecision medicinedrug licensingin silico drug designmulti-omics

Elixiron Immunotherapeutics Comparables

Compare Elixiron Immunotherapeutics with similar companies based on industry and business-model similarity.

Elixiron Immunotherapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Pilatus Biosciences	73%
SynOx Therapeutics	57%

View all Comparables

Elixiron Immunotherapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Jun 12, 2025
Grant	Jul 12, 2022
Series A Extension	Aug 23, 2021
Grant	Aug 25, 2020
Series A	Jul 31, 2019

View all Funding Rounds

Key People

Founding team and executive leadership

Cheng-Lung KU

Chief Science Officer, Co-Founder

Founding Team

Elixiron Immunotherapeutics Investors

Notable investors and investment history

Elixiron Immunotherapeutics investors
Investor	Rounds
Taiwania Capital	Series A, Series A Extension
Fubon Financial Holding Venture Capital	Series A Extension
CDIB Capital International	Series A
China Investment & Development Company, Limited	Series A Extension
Alzheimer's Association	Grant
Fubon Financial Holdings	Series A Extension

View all Investors

Elixiron Immunotherapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Elixiron Immunotherapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

Headquarters—

Employee Range23

Year Founded2017

Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?